CIM
DNLI icon

Contravisory Investment Management’s Denali Therapeutics DNLI Stock Holding History

Contravisory Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
14,674
+223
+2% +$4.58K 0.07% 163
2026
Q1 		$277K Buy
+14,451
New +$288K 0.06% 183

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Contravisory Investment Management's DNLI Position: Q2 2026 in Review

Contravisory Investment Management increased its Denali Therapeutics (DNLI) stake by 1.5% in Q2 2026, buying an estimated $4.58K and bringing the position to 14,674 shares worth $377K. The position accounts for 0.07% of the portfolio, ranked #163.

Contravisory Investment Management first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Contravisory Investment Management held 14,674 shares of Denali Therapeutics worth $377K as of Q2 2026.
  • Contravisory Investment Management bought 223 Denali Therapeutics shares in Q2 2026, an estimated $4.58K.
  • Denali Therapeutics made up 0.07% of Contravisory Investment Management's portfolio in Q2 2026, its #163 holding.
  • Contravisory Investment Management first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.